DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07127354

RecruitingPhase 4

The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality

The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial

Asset

GLP-1 / incretin class catch-all

Listed sites

3

Recruiting sites

3

Enrollment

132

estimated

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Inadequate bowel preparation

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07127354
Org study ID25-509

Timeline

Milestones

Study start2025-08-01actual
Study first posted2025-08-17actual
Last update posted2025-12-04actual
Primary completion2026-08estimated (month precision)
Study completion2026-08estimated (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Adult patient (Age 18 years or older)
•Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
•Using a GLP-1 or GIP agonist at a stable dose for at least one month

Exclusion criteria

•Unable to provide informed consent, e.g., dementia
•Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
•Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:

1. Cirrhosis

2. Parkinson's disease

3. Dementia

4. Tricyclic antidepressant use

5. Opioid use

6. Gastroparesis* or suspected gastric outlet obstruction on pre-procedure imaging (*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)

7. Previous colorectal surgery

8. Prior history of inadequate bowel preparation

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
6
Safety / tolerability / PK
3
Other (unclassified)
1

Safety / tolerability / PK

3 endpoints
Primary/protocol endpoint

Rate of inadequate bowel preparation

Time frame:During Surgery

event count, event

Secondary/protocol endpoint/low confidence

Median Ottawa bowel preparation score

Time frame:During Surgery

descriptive

Secondary/protocol endpoint

Other serious adverse events

Time frame:Day of the procedure up to 96 hours after the procedure.

Serious AEs (any)

event count, event

Other clinical outcomes

6 endpoints
Secondary/protocol endpoint

Median Boston bowel prep score

Time frame:During Surgery

descriptive

Secondary/protocol endpoint

Adenoma detection rate

Time frame:During Surgery

threshold achievement, improvement

Secondary/protocol endpoint

Colonoscope Insertion time

Time frame:During Surgery

descriptive

Secondary/protocol endpoint

Total procedure time

Time frame:During Surgery

descriptive

Secondary/protocol endpoint

Rate of unplanned endotracheal intubation

Time frame:During Surgery

event count, event

Secondary/protocol endpoint

hospitalization/emergency department evaluation/readmission for hypoxia or pnemonia within 96 hours after the procedure

Time frame:From the day of the procedure to 96 hours after the procedure

composite event, event

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Withdrawal time

Time frame:During Surgery

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.